A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PRV-015 IN ADULT PATIENTS WITH NON-RESPONSIVE CELIAC DISEASE AS AN ADJUNCT TO A GLUTEN-FREE DIET

Registry ID

PRV-015-002B

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

PROVENTION BIO, INC

Start date

2021-01-08

Last update

2020-10-02

Conditions

• CELIAC DISEASE

Related clinical trials

• A PHASE 2A/B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF SUBCUTANEOUS AMLITELIMAB IN ADULT PATIENTS WITH NON-RESPONSIVE CELIAC DISEASE AS AN ADJUNCT TO A GLUTEN-FREE DIET
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET
• RESTORATION OF IMPAIRED MICROBIOTA-MEDIATED ARYL HYDROCARBON RECEPTOR SIGNALING IN CELIAC DISEASE BY ORAL TRYPTOPHAN SUPPLEMENTATION: AN EXPLORATORY STUDY
• A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-062 FOR THE TREATMENT OF ACTIVE CELIAC DISEASE IN SUBJECTS ATTEMPTING A GLUTEN-FREE DIET
• A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY OF ALV003 TREATMENT IN SYMPTOMATIC CELIAC DISEASE PATIENTS MAINTAINED ON A GLUTEN-FREE DIET

View on source registry